References
- Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443. doi: 10.1016/j.jmii.2020.03.034
- Pagliano P, Scarpati G, Sellitto C, et al. Experimental pharmacotherapy for COVID-19: the latest advances. J Exp Pharmacol. 2021;13:1–13. doi: 10.2147/JEP.S255209
- Bhimraj A, Gallagher JC. Lack of benefit of fluvoxamine for COVID-19. JAMA. 2023;329(4):291–292. doi: 10.1001/jama.2022.23954
- Bartoletti M, Azap O, Barac A, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28(2):222–238. doi: 10.1016/j.cmi.2021.11.007
- Conti V, Corbi G, Sellitto C, et al. Effect of Tocilizumab in reducing the mortality rate in COVID-19 patients: a systematic review with meta-analysis. J Pers Med. 2021;11(7):628. doi: 10.3390/jpm11070628
- Sellitto C, Corbi G, Bertini N, et al. Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. J Chemother. 2022;35(5):1–14. doi: 10.1080/1120009X.2022.2121091
- Veklury [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/veklury
- RoActemra [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764
- Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–e51. doi: 10.1016/S2214-109X(21)00448-4
- Therapeutics and COVID-19: living Guideline [Internet]. Geneva: World Health Organization; [cited 2023 Nov 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.2
- Hirsch C, Park YS, Piechotta V, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022;6(6): CD014945. doi: 10.1002/14651858.CD014945.pub2
- Pagliano P, Sellitto C, Ascione T, et al. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov. 2022;17(12):1299–1311. doi: 10.1080/17460441.2022.2153828
- Refusal of the marketing authorisation for Lagevrio (molnupiravir) [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf
- Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clinical Infectious Diseases. 2023 Feb 8;76(3):e342–e349. Erratum in: Clin Infect Dis 2023;76(6):1158-1159. doi: 10.1093/cid/ciac443
- FDA updates on paxlovid for health care providers [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Nov 11]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers.
- Paxlovid, summary of product characteristics [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_it.pdf
- Conti V, Sellitto C, Torsiello M, et al. Identification of drug interaction adverse events in patients with COVID-19: a systematic review. JAMA Netw Open. 2022;5(4):e227970. doi: 10.1001/jamanetworkopen.2022.7970
- Cohen C, Pulliam J. COVID-19 infection, reinfection, and the transition to endemicity. Lancet. 2023;401(10379):798–800.
- Sotoodeh Ghorbani S, Taherpour N, Bayat S, et al. Epidemiologic characteristics of cases with re-infection, recurrence and hospital readmission due to COVID-19: a systematic review and meta-analysis. J Med Virol. 2021;94(1):44–53. doi: 10.1002/jmv.27281
- Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397(10280):1204–1212. doi: 10.1016/S0140-6736(21)00575-4
- Hashemian SMR, Sheida A, Taghizadieh M, et al. Paxlovid (Nirmatrelvir/Ritonavir): a new approach to covid-19 therapy? Biomed Pharmacother. 2023;162:114367. doi: 10.1016/j.biopha.2023.114367
- European Medicines Agency website [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en
- Italian Medicines Agency website [Internet]. Rome: Italian Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.aifa.gov.it/
- Clinicaltrials.gov website [Internet]. Bethesda (MD): Clinicaltrials.gov; [cited 2023 Nov 11]. Available from: https://www.clinicaltrials.gov/
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
- Salerno DM, Jennings DL, Lange NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022;22(8):2083–2088. doi: 10.1111/ajt.17027
- Prikis M, Cameron A. Paxlovid (Nirmatelvir/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report. Transplant Proc. 2022;54(6):1557–1560. doi: 10.1016/j.transproceed.2022.04.015
- Young C, Papiro T, Greenberg JH. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (paxlovid) for COVID-19 infection in a child with a kidney transplant. Pediatr Nephrol. 2023;38(4):1387–1388. doi: 10.1007/s00467-022-05712-0
- Wang AX, Koff A, Hao D, et al. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant. 2022;22(8):2117–2119. doi: 10.1111/ajt.16997
- Rose DT, Gandhi SM, Bedard RA, et al. Supratherapeutic tacrolimus concentrations with Nirmatrelvir/Ritonavir in solid organ transplant recipients requiring hospitalization: a case series using rifampin for reversal. Open Forum Infect Dis. 2022;9(7):ofac238. doi: 10.1093/ofid/ofac238
- Sindelar M, McCabe D, Carroll E. Tacrolimus drug-drug interaction with Nirmatrelvir/Ritonavir (Paxlovid™) managed with phenytoin. J Med Toxicol. 2023;19:45–48. doi: 10.1007/s13181-022-00922-2
- Stawiarski K, Avery R, Strout S, et al. Risks of paxlovid in a heart transplant recipient. J Heart Lung Transplant. 2023;42(1):30–32. doi: 10.1016/j.healun.2022.08.029
- Berar Yanay N, Bogner I, Saker K, et al. Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19. Clin Drug Investig. 2022;42:693–695. doi: 10.1007/s40261-022-01180-4
- Guzmán Cordero C, Saez-Torres de Vicente M. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series. Eur J Hosp Pharm. 2022;31(2):175–177. doi: 10.1136/ejhpharm-2022-003544
- Vazquez SR, Wilson AS, Witt DM. Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series. J Thromb Thrombolysis. 2022;54(4):583–586. doi: 10.1007/s11239-022-02707-4
- Liu CI, Goh KK, Chen CH. Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: a case report with a literature review. Front Psychiatry. 2022;13:1096006. doi: 10.3389/fpsyt.2022.1096006
- Cole JB, Meiners RB, Bangh SA. Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug-drug interaction. Clin Toxicol (Phila). 2022 Aug;60:985–986. doi: 10.1080/15563650.2022.2057323
- Kane AM, Keenan EM, Lee K, et al. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: a retrospective observational study. J Am Coll Clin Pharm. 2023;6:29–33. doi: 10.1002/jac5.1729
- Habeeb E, Gabardi S, Townsend K, et al. Potential effects of remdesivir on tacrolimus exposure in transplant recipients with COVID-19 infection. Kidney Int Rep. 2023;8:1315–1322. doi: 10.1016/j.ekir.2023.04.028
- SR SK, A PA, S B, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases. Diabetes Metab Syndr. 2022 Mar;16(3):102451. doi: 10.1016/j.dsx.2022.102451
- Yalcin N, Allegaert K. COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed. Eur J Clin Pharmacol. 2022 Oct;78(10):1697–1701. doi: 10.1007/s00228-022-03370-7
- WHO updates guidelines on treatments for COVID-19 [Internet]. Geneva: World Health Organization; [cited 2023 Nov 11]. Available from: https://www.who.int/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19 (Accessed Nov, 2023)
- Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29(2):334–343. doi: 10.1038/s41591-022-02156-9
- Davies EA, O’Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80:796–807. doi: 10.1111/bcp.12596
- Sürmelioğlu N, Yalçın N, Kuşçu F, et al. Physicians’ knowledge of potential COVID-19 drug-drug interactions: an online survey in turkey. Postgrad Med. 2021 Mar;133:237–241. doi: 10.1080/00325481.2020.1807809
- Loos NHC, Beijnen JH, Schinkel AH. The mechanism-based inactivation of CYP3A4 by Ritonavir: what mechanism? Int J Mol Sci. 2022;23(17):9866. doi: 10.3390/ijms23179866
- Stefanelli B, Sellitto C, De Bellis E, et al. Concomitant administration of capecitabine and folate supplements: need to encourage medication reconciliation. Pharmaceuticals (Basel). 2022;15(11):1388. doi: 10.3390/ph15111388
- Bourne RS, Jennings JK, Panagioti M, et al. Medication-related interventions to improve medication safety and patient outcomes on transition from adult intensive care settings: a systematic review and meta-analysis. BMJ Qual Saf. 2022;31(8):609–622. doi: 10.1136/bmjqs-2021-013760
- Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/Ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant. 2022;22:1925–1926. doi: 10.1111/ajt.16955
- Fishbane S, Hirsch JS, Nair V. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am J Kidney Dis. 2022;79(4):480–482. doi: 10.1053/j.ajkd.2022.01.001
- Advagraf, summary of product characteristics. Rome: Italian Medicines Agency. [cited 2023 Nov 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000771_038218_RCP.pdf&sys=m0b1l3
- AST statement on oral antiviral therapy for COVID-19 for organ transplant [Internet]. American Society of Transplantation. [cited 2023 Nov 11]. Available from: https://www.myast.org/sites/default/files/AST%20Statement%20on%20Oral%20Antiviral%20Therapy%20for%20COVID%20Jan%204%20%282%29.pdf
- Veklury, summary of product characteristics [Internet]. Amsterdam: European Medicines Agency; [cited 2023 Nov 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_it.pdf
- Fluvoxamina, summary of product characteristics [Internet]. Rome: Italian Medicines Agency; [cited 2023 Nov 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001561_034669_FI.pdf&sys=m0b1l3
- Euphyllina rilcon, summary of product characteristics [Internet]. Rome: Italian Medicines Agency; [cited 2023 Nov 11]. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000348_008730_RCP.pdf&retry=0&sys=m0b1l3
- Drug-drug interactions between ritonavir-boosted nirmatrelvir (paxlovid) and concomitant medications. Bethesda (MD): National Institute Health; [cited 2023 Nov 11]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir–paxlovid-/paxlovid-drug-drug-interactions
- Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G, et al. Drug-drug Interactions between COVID-19 treatments and antidepressants, mood stabilizers/anticonvulsants, and benzodiazepines: integrated evidence from 3 databases. Pharmacopsychiatry. 2022 Jan;55(1):40–47.
- Fırat O, Yalçın N, Demirkan KCOVID-19 & antiepileptic drugs: Should we pay attention? Seizure. 2020 Aug;80:240–241. doi: 10.1016/j.seizure.2020.07.005
- Chatterjee S, Kar SK, Prakash AJ, et al. Drug-drug interaction between psychotropic medications and medications used in COVID-19: comparison of online databases. Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):534–543. doi: 10.9758/cpn.22.1014